Efficacy and Safety of Salmeterol/fluticasone Combination Therapy in Infants and Preschool Children with Asthma Insufficiently Controlled by Inhaled Corticosteroids

Abstract

Background: Clinical evidences of inhaled salmeterol/fluticasone propionate combination (SFC) therapy are insufficient in early childhood asthma.

Objectives: To examine the effects of SFC50, a combination product of salmeterol xinafoate (50 μg/day) and fluticasone propionate (100 μg/day), in infants and preschool children with asthma.

Methods: The study was conducted at 31 sites in Japan. 35 patients (6 months to 5 years old) with asthma insufficiently controlled by inhaled corticosteroids (100 μg/day) were initiated to treat with SFC50 twice a day for 12 weeks with pressurized metered dose inhalers. The efficacy of SFC50 was assessed using nighttime sleep disorder score as the primary endpoint and the other efficacy measurements. The safety measurement included the incidences of adverse event (AE).

Results: Mean patient age was 3.1 years, and 94.2% had mild-to-moderate persistent asthma (atopic type: 65.7%). Nighttime sleep disorder scores, assessed by a nighttime sleep diary, significantly decreased after treatment with SFC50 throughout the study period (p<0.01). SFC50 also significantly improved other efficacy outcomes including asthma symptom score, frequency of short-acting beta-agonist treatment, frequency of unscheduled visits to clinic, frequency of exacerbation due to virus infection, asthma control score and patient QOL score (p<0.01). AEs of cold, upper respiratory inflammation and asthmatic attack occurred in each of the 3 patients (8.6%); however, these were not regarded as treatment-related AEs.

Conclusions: SFC50 improved nighttime sleep disorder score and other efficacy outcome measures with no safety concerns. The results suggest that SFC50 treatment is useful to control the mild-to-moderate asthma in infant and preschool-aged children.

Key words

salmeterol/fluticasone combination - asthma - infant - preschool children - nighttime sleep disorder score - long-acting beta-agonist - inhaled corticosteroid

• References

• 1 World Health Organization (WHO). Asthma. Fact sheet no. 307. Updated November 2013. Available from: http://www.who.int/mediacentre/factsheets/fs307/en/ Accessed June 22, 2015
• 2 Spahn JD, Covar R. Clinical assessment of asthma progression in children and adults. J Allergy Clin Immunol 2008; 121: 548-557
• 3 Akinbami LJ, Moorman JE, Garbe PL, Sondik EJ. Status of childhood asthma in the United States, 1980–2007. Pediatrics 2009; 123 (Suppl. 03) S131-S145
• 4 Cave AJ, Atkinson LL. Asthma in preschool children: a review of the diagnostic challenges. J Am Board Fam Med 2014; 27: 538-548
• 5 Hafkamp-de Groen E, Mohangoo AD, de Jongste JC, van der Wouden JC, Moll HA, Jaddoe VW, Hofman A, Koning H, Raat H. Early detection and counselling intervention of asthma symptoms in preschool children: study design of a cluster randomised controlled trial. BMC Public Health 2010; 10: 555 Available from http://www.biomedcentral.com/1471-2458/10/555
• 6 Bacharier LB, Guilbert TW. Diagnosis and management of early asthma in preschool-aged children. J Allergy Clin Immunol 2012; 130: 287-296
• 7 Horner CC, Bacharier LB. Diagnosis and management of asthma in preschool and school-age children: focus on the 2007 NAEPP Guidelines. Curr Opin Pulm Med 2009; 15: 52-56
• 8 Label for ADVAIR DISKUS (fluticasone propionate and salmeterol inhalation powder). GlaxoSmithKline
• 9 Yoshihara S, Kanno N, Fukuda H, Yamada Y, Fukuda N, Tsuchiya T, Arisaka O. Development and validation of a nighttime sleep diary in asthmatic children. Pediatr Allergy Immunol 2011; 22: 667-670
• 10 Liu AH, Zeiger R, Sorkness C, Mahr T, Ostrom N, Burgess S, Rosenzweig JC, Manjunath R. Development and cross-sectional validation of the Childhood Asthma Control Test. J Allergy Clin Immunol 2007; 119: 817-825
• 11 Yoshihara S, Kanno N, Yamada Y, Fukuda N, Tsuchiya T, Fukuda H, Abe T, Ando T, Asai H, Iimura A, Nishida M, Ono M, Sato Y, Arisaka O. Benefits of budesonide inhalation suspension treatment on nocturnal sleep disturbance in young children with bronchial asthma. Jpn J Pediatr Allergy Clin Immunol 2010; 24: 753-762 [in Japanese]
• 12 Package insert for Adoair^® Diskus^®/Aerosol (salmeterol/fluticasone combination). GlaxoSmithKline K.K. [in Japanese]
• 13 Global Initiative for Asthma (GINA). 2012 Update: global strategy for asthma management and prevention. Available from: http://www.ginasthma.org/documents/5/documents_variants/37 Accessed June 22, 2015
• 14 Osman L, Silverman M. Measuring quality of life for young children with asthma and their families. Eur Respir J Suppl 1996; 21: 35s-41s
• 15 Merikallio VJ, Mustalahti K, Remes ST, Valovirta EJ, Kaila M. Comparison of quality of life between asthmatic and healthy school children. Pediatr Allergy Immunol 2005; 16: 332-340
• 16 Busse WW, Morgan WJ, Gergen PJ, Mitchell HE, Gern JE, Liu AH, Gruchalla RS, Kattan M, Teach SJ, Pongracic JA, Chmiel JF, Steinbach SF, Calatroni A, Togias A, Thompson KM, Szefler SJ, Sorkness CA. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med 2011; 364: 1005-1015
• 17 Hamasaki Y, Kohno Y, Ebisawa M, Kondo N, Nishima S, Nishimuta T, Morikawa A. Japanese Society of Allergology; Japanese Society of Pediatric Allergy and Clinical Immunology. Japanese Guideline for Childhood Asthma 2014. Allergol Int 2014; 63: 335-356
• 18 Linder JE, Kraft DC, Mohamed Y, Lu Z, Heil L, Tollefson S, Saville BR, Wright PF, Williams JV, Miller EK. Human rhinovirus C: age, season, and lower respiratory illness over the past 3 decades. J Allergy Clin Immunol 2013; 131: 69-77
• 19 Jackson DJ, Gangnon RE, Evans MD, Roberg KA, Anderson EL, Pappas TE, Printz MC, Lee WM, Shult PA, Reisdorf E, Carlson-Dakes KT, Salazar LP, DaSilva DF, Tisler CJ, Gern JE, Lemanske Jr RF. Wheezing rhinovirus illnesses in early life predict asthma development in high-risk children. Am J Respir Crit Care Med 2008; 178: 667-672
• 20 Papi A, Contoli M, Adcock IM, Bellettato C, Padovani A, Casolari P, Stanciu LA, Barnes PJ, Johnston SL, Ito K, Caramori G. Rhinovirus infection causes steroid resistance in airway epithelium through nuclear factor kB and c-Jun N-terminal kinase activation. J Allergy Clin Immunol 2013; 132: 1075-1085
• 21 Simoes EA, Groothuis JR, Carbonell-Estrany X, Rieger CH, Mitchell I, Fredrick LM, Kimpen JL. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. J Pediatr 2007; 151: 34-42
• 22 Yoshihara S, Kusuda S, Mochizuki H, Okada K, Nishima S, Simões EA. C-CREW Investigators. Effect of palivizumab prophylaxis on subsequent recurrent wheezing in preterm infants. Pediatrics 2013; 132: 811-818
• 23 Lemanske Jr RF, Mauger DT, Sorkness CA, Jackson DJ, Boehmer SJ, Martinez FD, Strunk RC, Szefler SJ, Zeiger RS, Bacharier LB, Covar RA, Guilbert TW, Larsen G, Morgan WJ, Moss MH, Spahn JD, Taussig LM. Childhood Asthma Research and Education (CARE) Network of the National Heart, Lung, and Blood Institute. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N Engl J Med 2010; 362: 975-985